AVBP
ArriVent BioPharma, Inc.23.11
-0.53-2.24%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
954.01MP/E (TTM)
-Basic EPS (TTM)
-4.15Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Firmonertinib Phase 1b data shines
ArriVent BioPharma unveiled final Phase 1b data for firmonertinib in first-line EGFR PACC mutant NSCLC, showing 16.0 months median PFS, 68.2% confirmed ORR, and 14.6 months duration of response at 240 mg dose by BICR. CNS responses included 42.9% ORR and 35.7% complete responses in evaluable patients, while 82% achieved ctDNA clearance across PACC mutation types. The drug's manageable safety profile aligns with EGFR-TKI class. First patient enrollment in the pivotal Phase 3 ALPACCA trial is slated for H2 2025. Yet risks persist in clinical outcomes.
8-K
Q2 results advance firmonertinib trials
ArriVent BioPharma reported Q2 2025 financials, highlighting positive interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC, showing meaningful progression-free survival and CNS responses. The company dosed its first patient in the Phase 1 trial for ARR-217, a CDH17-targeted ADC for gastrointestinal tumors, while advancing pivotal studies with topline Exon 20 data due early 2026. Cash stood at $254.5 million as of June 30, bolstered by $81.1 million from a July offering, funding operations to mid-2027. Pipeline momentum builds, yet clinical risks persist.
10-Q
Q2 FY2025 results
ArriVent BioPharma posted a Q2 net loss of $31.4 million, up 43% year-over-year from $21.9 million, driven by research and development expenses climbing to $27.7 million from $21.8 million as the firm ramps up clinical trials for firmonertinib and discovery programs, while general and administrative costs rose to $5.9 million from $3.9 million on higher personnel and professional fees. For the first half, the net loss widened to $95.8 million from $39.3 million, reflecting a $40 million upfront payment for the January 2025 Lepu Biopharma license of ARR-217, an antibody drug conjugate for gastrointestinal cancers outside greater China, alongside $1 million in milestone payments. Cash and equivalents stood at $112.8 million at quarter-end, with total liquidity including marketable securities at $254.5 million, bolstered by $81.9 million from at-the-market equity sales; no debt was drawn on the new $75 million Silicon Valley Bank facility. The company plans to initiate the ALPACCA Phase 3 trial for firmonertinib in PACC-mutated NSCLC in late 2025. Yet regulatory hurdles in oncology approvals loom large.
ABVC
ABVC Biopharma, Inc.
2.06-0.01
ACRV
Acrivon Therapeutics, Inc.
2.42-0.15
APLM
Apollomics Inc.
17.02+0.92
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
ARVN
Arvinas, Inc.
11.90-0.44
MNPR
Monopar Therapeutics Inc.
71.47-3.65
NUVB
Nuvation Bio Inc.
8.66+0.15
NUVL
Nuvalent, Inc.
102.63-2.34
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
TRAW
Traws Pharma, Inc.
2.20-0.04